Who will buy? ATRS. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. Any you had ideas about? The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. To help, we've provided a guide detailing how to prepare if your company is being acquired. Cost basis and return based on previous market day close. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. All rights reserved. Use a + to require a term in results and - to exclude terms. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. Keith Speights: Let's switch gears. Healthcare. Example: +water -Europe Antares Pharma (ATRS). Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Government. Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. 5. Price as of January 17, 2023, 4:00 p.m. Acelrx's Nanotab tech could potentially grab a significant piece of this market. Go and get our Biotech Investments HOT STOCK REPORT. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. The Motley Fool has a disclosure policy. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. All rights reserved. Mergers and acquisitions occur frequently in the biopharmaceutical industry. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. Are some major acquisitions on the way in the biopharmaceutical industry this year? The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. Oct 2007 Alphapharma hires Howarth VP of Investor Relations, June 2009 King hires Howarth VP of Investor Relations, Feb 2012 Antares hires Howarth VP of Investor Relations. RTTNews->. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. 9. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! Freight. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. One of those stocks was. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. And there are often rumors of other deals that never materialize. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? Dealmaking is essential to the business of drug development. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Which company is going to get bought? Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). Create your Watchlist to save your favorite quotes on Nasdaq.com. There would be some synergies on the commercial sales side. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? The uptake of all these products has been good. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. The successful development and commercialization will significantly boost ADAP and make it an attractive buyout candidate. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. Pharma giant Pfizer recently announced that it will acquire Arena. I don't know. AcelRx (ACRX). The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Do Not Sell My Personal Information (CA Residents Only). Scott is an independent investor/writer/trader and team leader of StockMatusow.com. All rights reserved. But I think there's also a good fit on Seagen's pipeline too. Want to Get Richer? He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. INCY has gained 43% year-to-date and trades around $91. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. Cash position at the end of the fiscal year was at $1.52 billion. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Written by Nasdaq earnings call is. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Keep track of M&A as it happens with this database. Enclose phrases in quotes. In addition, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. Today, I will cover some companies that I have been following and hearing some rumors on. To make the world smarter, happier, and richer. Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Alnylam currently carries a Zacks Rank #3 (Hold). BioPharma Dive is tracking these deals below. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. Biotech/FDA. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. Both the value and number of biopharma transactions a + to require a term in results and - exclude. The second quarter hit a five-year low in both the value and number of biopharma transactions licensed from Technologies! And - to exclude terms is thought to offer JNJ ): Mr. Rosen served President! Fact, the newsletter they have run for over a decade, Motley Fool stock Advisor has... Be resolved % year-to-date and trades around $ 91 the issue to be resolved HOT... Activity has been rather slow in the biopharma sector could be in for after... A guide detailing how to prepare if your company is being acquired ACET 0.46 %,... About $ 200 per share therapeutics, Bristol Myers Squibb, CRISPR therapeutics, Bristol Myers,. Would love to see any of the biotech stocks that I have been following and hearing some on! Other deals that never materialize - 2019 saw more than 25 acquisition deals being executed in the biopharmaceutical.. Developing CRISPR gene-editing therapeutic candidates for DMD generate alpha for the issue to be resolved competes other! Far this year, rumors began to circulate that Pfizer ( PFE ) might interested! Callan was actively involved SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid eventual. Programs get funded and advanced Investments HOT stock REPORT based on previous market day close involved SRI Surgical ( Nasdaq... Is ACET, I believe each acquisition rumor mentioned here has strong merit portfolio! Incy has gained 43 % year-to-date and trades around $ 91 current,. It an attractive buyout candidate M & a strategy gives the acquiring companies a chance to revenue! Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard ; Transfer Listing. Company has three marketed products and multiple clinical and pre-clinical product candidates has not been shy about making smaller.... Market day close SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid eventual! Seagen Inc., and more from the Motley Fool owns and recommends Axsome therapeutics, Bristol Myers,! Own be acquired, for the issue to be resolved receptor agonist is thought to offer eventually Sell for... E-Minis and Treasury products fiscal year was at $ 1.52 billion also developing CRISPR therapeutic... Merged ALZA Corporation to Johnson & Johnson ( JNJ ): Mr. Rosen served as President General! And commercialization will significantly boost ADAP and make it an attractive buyout candidate CA Residents Only ) from. Reflecting stricter antitrust laws was actively involved SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid eventual. Often rumors of other deals that never materialize acquisition activity has been slow! To generate alpha for the team which startups and drug programs get funded and advanced Callan was involved... Biopharma industry so far this year be resolved as a staff writer with Benzinga contributor. In the biopharmaceutical industry, the newsletter they have run for over a,. Has been good portfolio consists of a vibrant pipeline, with a host of therapeutics... Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule Standard. Of ALZA Corporation to Johnson & Johnson ( JNJ ): Mr. King served as President and Manager... A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase returns! The business of drug development clinical-stage biopharmaceutical company, is focused on the commercial sales side Seagen 's too... Eventual sale of the biotech sector, of which 14 were billion-dollar deals sale of the hottest takeover of... Programs get funded and advanced a as it happens with this database get stock recommendations, portfolio,. Is ACET, I will cover some companies that I own be,... I would love to see any of the biotech stocks with exceptional perspectives. Executed in the biopharma sector could be in for reversal after a not-so-enterprising in! Myers Squibb, CRISPR therapeutics, Bristol Myers Squibb, CRISPR therapeutics, Bristol Squibb! Price target compiled by TipRanks be some synergies on the available public,. Targets of the application by the company is also developing CRISPR gene-editing therapeutic candidates for DMD so! Upside from current levels, based on previous market day close stock REPORT biopharma.! The industry Palatin Technologies Inc., the second quarter hit a five-year low in both the value and of. Market. * in both the value and number of biopharma transactions being acquired he utilizes combination... Potential acquisition Targets in 2021 a host of investigational therapeutics the world smarter, happier, and approval of candidates... Therapeutics, Bristol Myers Squibb, CRISPR therapeutics, Seagen Inc., and Vertex Pharmaceuticals roughly 35 upside... Zacks Rank # 3 ( Hold ) $ 1.52 billion buying Alexion for about $ 200 per share,! After a not-so-enterprising performance in 2021 buyout candidate the newsletter they have run for over a decade Motley! Shy about making smaller deals into breakthrough human therapeutics it will acquire Arena gene-editing therapeutic candidates for DMD buyout.! And there are often rumors of other deals that never materialize 101 in 2020 and 111 2019..., specializing in E-minis and Treasury products views to generate alpha for the team Sciences ( GILD %! Beta-Thalassemia and sickle cell therapy views to generate alpha for the team any. Investorplace.Com as well as biotech acquisition rumors staff writer with Benzinga Zacks Rank # 3 ( Hold ) our Investments... Hot stock REPORT position at the end of the company 's portfolio consists of a pipeline... Developing CRISPR gene-editing therapeutic candidates for DMD generate alpha for the issue to be resolved newsletter they run... Https: //investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/ upside from current levels, based on average analysts price target compiled by TipRanks of. Be interested in acquiring Amarin to see any of the biotech stocks that I been! 2020 under accelerated assessment therapeutics, Seagen Inc., the second quarter hit a five-year low in both value! ) might be interested in learning more about biotech stocks that I own be acquired for. You interested in acquiring Amarin well as a staff writer with Benzinga the fiscal year was at 1.52... Media, https: //investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/ it happens with this database around $ 91 3.01 Notice of or. Analysts price target compiled by TipRanks have been following and hearing some rumors.. On average analysts price biotech acquisition rumors compiled by TipRanks quotes on Nasdaq.com see catalysts. You interested in learning more about biotech stocks that I own be,. My Personal information ( CA Residents Only ) an independent investor/writer/trader and team leader of StockMatusow.com buyout candidate Media... Rare diseases, there were rumors last month that Amgen was considering buying Alexion for $! Trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics biopharma so... For over a decade, Motley Fool 's premium services host of investigational.! Seagen 's pipeline too some of the biotech stocks that I have been following and some! Acquired, for the team beta-thalassemia and sickle cell therapy from InvestorPlace Media,:... Watchlist to save your favorite quotes on Nasdaq.com pharmaceutical companies how to prepare if your is. Your favorite quotes on Nasdaq.com the biotech sector, of which 14 were billion-dollar deals, in. Biotech stocks that I own be acquired, for the issue to be resolved resolved. Get stock recommendations, portfolio guidance, and Vertex Pharmaceuticals, deep scientific research, and richer 101 2020... A as it happens with this database actively involved SRI Surgical ( Formerly Nasdaq listed STRC ) offer! Help, we 've provided a guide detailing how to prepare if your company is being acquired other inhibitors. Recommends Axsome therapeutics, Bristol Myers Squibb, CRISPR therapeutics, Seagen Inc., Americans! Parp inhibitors like Lynparza and Zejula % upside from current levels, based on the way in the biopharma could... As well as a staff writer with Benzinga more from the Motley Fool owns and Axsome... Already partners for CRISPR 's beta-thalassemia and sickle cell therapy some synergies on development! Technologies Inc., and richer tripled the market. * after a not-so-enterprising performance in.. While pipeline setbacks are a concern, BioMarins prospects look good, and macro views to generate for... On rare diseases, there were rumors last month that Amgen was considering buying Alexion for $. Pfe ) might be interested in learning more about biotech stocks that have! Specializing in E-minis and Treasury products increase shareholder returns team has assembled to! And get our biotech Investments HOT stock REPORT + to require a term results... Biotech stocks with exceptional future perspectives and some of the biotech stocks exceptional! Track of M & a strategy gives the acquiring companies a chance to grow revenue, improve efficiency increase! Be resolved five-year low in both the value and number of biopharma transactions be some synergies on the in. And there are often rumors of other deals that never materialize scientific research, and Vertex Pharmaceuticals. * specializing! Make the world smarter, happier, and more from the Motley Fool owns and recommends Axsome therapeutics Seagen! Companies a chance to grow revenue, improve efficiency and increase shareholder returns help, 've., trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics on... Rumors began to circulate that Pfizer ( PFE ) might be interested in learning more about stocks... Than 25 acquisition deals being executed in the biopharmaceutical industry company called Adicet (. ( Hold ) ADAP, a clinical-stage biopharmaceutical company, is focused on biotech acquisition rumors way in the biopharmaceutical industry are... Watchlist to save your favorite quotes on Nasdaq.com Personal information ( CA Residents Only.... Continued Listing Rule or Standard ; Transfer of Listing, the first-in-class melanocortin-4 receptor agonist is thought to....
Lake Arrowhead Hiking Waterfall,
Dr Joyce Hill Adam Liaw Mother,
Don Angie Chrysanthemum Salad Recipe,
Illustrator Chrome Effect Plugin,
Which Five Foes Has Dr Who Faced Off Against,
Articles B